Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Survodutide

Investigational

Glucagon/GLP-1 dual agonist

Also known as: BI 456906, BI-456906, GLXC-27923

Evidence score

63/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 29 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Survodutide, also known as BI 456906, is an investigational injectable peptide developed by Boehringer Ingelheim. It activates both the glucagon receptor and the GLP-1 receptor, which is thought to reduce appetite while also increasing energy expenditure and fat processing in the liver.

What the evidence shows

Automatic summaryLimited human data

Survodutide is not FDA-approved. Phase 2 trials reported weight loss and improvements in fatty liver disease, and it has reached Phase 3 among 28 registered human trials, but those later-stage results are not yet conclusive and long-term safety is not established.

Key facts

Molecular formula

C192H289N47O61

Molecular weight

4232 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

29registered studies

Phase 3most advanced phase

18completed (sample)

4recruiting (sample)

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Phase 1CompletedNCT06772532

A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood

Phase 1CompletedNCT05896384

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase 1CompletedNCT06492135

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

Phase 1CompletedNCT07413913

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

93papers referencing Survodutide

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

N Engl J Med2024

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

Diabetes Care2024

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

Lancet Diabetes Endocrinol2024

Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Diabetologia2024

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.